NCT07652125 — Guangdong Association of Clinical Trials cancer immunotherapy trial
RGL-270 + ICI in Advanced NSCLC
Registry record
| Registry ID | NCT07652125 ↗ |
|---|---|
| Lead sponsor | Guangdong Association of Clinical Trials |
| Collaborators | Shanghai Regenelead Theraples,Co,Ltd. |
| Phase | Phase NA |
| Status | Recruiting |
| Indication | NSCLC |
| Enrollment | 40 participants (target) |
| Start date | 2025-10-25 |
| Primary completion | 2027-12-31 (est.) |
| Last registry update | 30 Jun 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07652125), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07652125?
NCT07652125 (RGL-270 + ICI in Advanced NSCLC) is registered on ClinicalTrials.gov as Phase NA, sponsored by Guangdong Association of Clinical Trials.
Is NCT07652125 recruiting?
As of the 2026-06-30 registry update, NCT07652125 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07652125?
The lead sponsor is Guangdong Association of Clinical Trials. Collaborators: Shanghai Regenelead Theraples,Co,Ltd..
What condition does NCT07652125 study?
The registered condition is NSCLC. Primary completion is listed as 2027-12-31 (estimated).
Are results available for NCT07652125?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07652125.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.